Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The transcription factor Rfx7 limits metabolism of NK cells and promotes their maintenance and immunity

Nature Immunology volume 19, pages 809–820 (2018)Cite this article

Subjects

Abstract

Regulatory factor X 7 (Rfx7) is an uncharacterized transcription factor belonging to a family involved in ciliogenesis and immunity. Here, we found that deletion of Rfx7 leads to a decrease in natural killer (NK) cell maintenance and immunity in vivo. Genomic approaches showed that Rfx7 coordinated a transcriptional network controlling cell metabolism. Rfx7–/– NK lymphocytes presented increased size, granularity, proliferation, and energetic state, whereas genetic reduction of mTOR activity mitigated those defects. Notably, Rfx7-deficient NK lymphocytes were rescued by interleukin 15 through engagement of the Janus kinase (Jak) pathway, thus revealing the importance of this signaling for maintenance of such spontaneously activated NK cells. Rfx7 therefore emerges as a novel transcriptional regulator of NK cell homeostasis and metabolic quiescence.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Rfx7 cellular and subcellular profiling.
Fig. 2: NK cells are strongly reduced in Vav Rfx7fl/fl mice.
Fig. 3: Rfx7 deficiency affects mature NK cell survival.
Fig. 4: Rfx7-deficient NK cells efficiently respond to high IL-15 doses.
Fig. 5: Rfx7-deficient NK cells exhibit deregulated expression of metabolism-related genes.
Fig. 6: Validation of Rfx7-target genes identified in NK cells.
Fig. 7: Rfx7-deficient NK cells exhibit deregulated metabolism and require Jak1/3 signaling for survival.
Fig. 8: NK cell-mediated immunity is compromised in Vav Rfx7fl/fl mice.

References

  1. Emery, P. et al. A consensus motif in the RFX DNA binding domain and binding domain mutants with altered specificity. Mol. Cell. Biol. 16, 4486–4494 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Aftab, S., Semenec, L., Chu, J. S. & Chen, N. Identification and characterization of novel human tissue-specific RFX transcription factors. BMC Evol. Biol. 8, 226 (2008).

    PubMed  PubMed Central  Google Scholar 

  3. Dorn, A. et al. Conserved major histocompatibility complex class II boxes: X and Y--are transcriptional control elements and specifically bind nuclear proteins. Proc. Natl Acad. Sci. USA 84, 6249–6253 (1987).

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Badis, G. et al. Diversity and complexity in DNA recognition by transcription factors. Science 324, 1720–1723 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Chung, M. I. et al. Coordinated genomic control of ciliogenesis and cell movement by RFX2. eLife 3, e01439 (2014).

    PubMed  PubMed Central  Google Scholar 

  6. Kistler, W. S. et al. RFX2 is a major transcriptional regulator of spermiogenesis. PLoS. Genet. 11, e1005368 (2015).

    PubMed  PubMed Central  Google Scholar 

  7. Blackshear, P. J. et al. Graded phenotypic response to partial and complete deficiency of a brain-specific transcript variant of the winged helix transcription factor RFX4. Development 130, 4539–4552 (2003).

    CAS  PubMed  Google Scholar 

  8. Ashique, A. M. et al. The Rfx4 transcription factor modulates Shh signaling by regional control of ciliogenesis. Sci. Signal. 2, ra70 (2009).

    PubMed  Google Scholar 

  9. Bonnafe, E. et al. The transcription factor RFX3 directs nodal cilium development and left-right asymmetry specification. Mol. Cell. Biol. 24, 4417–4427 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Baas, D. et al. A deficiency in RFX3 causes hydrocephalus associated with abnormal differentiation of ependymal cells. Eur. J. Neurosci. 24, 1020–1030 (2006).

    CAS  PubMed  Google Scholar 

  11. Ait-Lounis, A. et al. Novel function of the ciliogenic transcription factor RFX3 in development of the endocrine pancreas. Diabetes 56, 950–959 (2007).

    CAS  PubMed  Google Scholar 

  12. Smith, S. B. et al. Rfx6 directs islet formation and insulin production in mice and humans. Nature 463, 775–780 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Reith, W. & Mach, B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu. Rev. Immunol. 19, 331–373 (2001).

    CAS  PubMed  Google Scholar 

  14. Ludigs, K. et al. NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module. PLoS. Genet. 11, e1005088 (2015).

    PubMed  PubMed Central  Google Scholar 

  15. Manojlovic, Z., Earwood, R., Kato, A., Stefanovic, B. & Kato, Y. RFX7 is required for the formation of cilia in the neural tube. Mech. Dev. 132, 28–37 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Bullinger, L. et al. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia 24, 438–449 (2010).

    CAS  PubMed  Google Scholar 

  17. Crowther-Swanepoel, D. et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat. Genet. 42, 132–136 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Slager, S. L. et al. Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood 120, 843–846 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Berndt, S. I. et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat. Genet. 45, 868–876 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 518, 187–196 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Yau, C. et al. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 12, R85 (2010).

    PubMed  PubMed Central  Google Scholar 

  22. Rogers, L. M., Olivier, A. K., Meyerholz, D. K. & Dupuy, A. J. Adaptive immunity does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer. J. Immunol. 190, 4393–4399 (2013).

    CAS  PubMed  Google Scholar 

  23. Rusiniak, M. E., Kunnev, D., Freeland, A., Cady, G. K. & Pruitt, S. C. Mcm2 deficiency results in short deletions allowing high resolution identification of genes contributing to lymphoblastic lymphoma. Oncogene 31, 4034–4044 (2012).

    CAS  PubMed  Google Scholar 

  24. Zerbino, D. R. et al. Ensembl 2018. Nucleic Acids Res. 46, D754–D761 (2018).

    CAS  PubMed  Google Scholar 

  25. Wu, C. et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 10, R130 (2009).

    PubMed  PubMed Central  Google Scholar 

  26. Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924–1927 (2006).

    CAS  PubMed  Google Scholar 

  27. Rota, G. et al. T Cell priming by activated nlrc5-deficient dendritic cells is unaffected despite partially reduced MHC class I levels. J. Immunol. 196, 2939–2946 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Yang, M. et al. NK cell development requires Tsc1-dependent negative regulation of IL-15-triggered mTORC1 activation. Nat. Commun. 7, 12730 (2016).

    PubMed  PubMed Central  Google Scholar 

  29. Dai, Q. et al. mTOR/Raptor signaling is critical for skeletogenesis in mice through the regulation of Runx2 expression. Cell. Death Differ. 24, 1886–1899 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Polak, P. et al. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell. Metab. 8, 399–410 (2008).

    CAS  PubMed  Google Scholar 

  31. Inoki, K. et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J. Clin. Invest. 121, 2181–2196 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Sathe, P. et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat. Commun. 5, 4539 (2014).

    CAS  PubMed  Google Scholar 

  33. Doucey, M. A. et al. Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat. Immunol. 5, 328–336 (2004).

    CAS  PubMed  Google Scholar 

  34. The UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 45, D158–D169 (2017).

    Google Scholar 

  35. Yang, K., Neale, G., Green, D. R., He, W. & Chi, H. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat. Immunol. 12, 888–897 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Brugarolas, J. et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes. Dev. 18, 2893–2904 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Boros, K., Lacaud, G. & Kouskoff, V. The transcription factor Mxd4 controls the proliferation of the first blood precursors at the onset of hematopoietic development in vitro. Exp. Hematol. 39, 1090–1100 (2011).

    CAS  PubMed  Google Scholar 

  38. Hurlin, P. J. et al. Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J. 14, 5646–5659 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Wei, H. et al. Cutting edge: Foxp1 controls naive CD8+ T cell quiescence by simultaneously repressing key pathways in cellular metabolism and cell cycle Progression. J. Immunol. 196, 3537–3541 (2016).

    CAS  PubMed  Google Scholar 

  40. Zhu, Z. et al. PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein. Biochem. Biophys. Res. Commun. 358, 66–72 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Lauth, M. et al. DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nat. Struct. Mol. Biol. 17, 718–725 (2010).

    CAS  PubMed  Google Scholar 

  42. Keramati, A. R. et al. A form of the metabolic syndrome associated with mutations in DYRK1B. N. Engl. J. Med. 370, 1909–1919 (2014).

    PubMed  PubMed Central  Google Scholar 

  43. Colpitts, S. L. et al. Transcriptional regulation of IL-15 expression during hematopoiesis. J. Immunol. 191, 3017–3024 (2013).

    CAS  PubMed  Google Scholar 

  44. Eckelhart, E. et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood 117, 1565–1573 (2011).

    CAS  PubMed  Google Scholar 

  45. Marçais, A. et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat. Immunol. 15, 749–757 (2014).

    PubMed  PubMed Central  Google Scholar 

  46. Huntington, N. D. et al. Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat. Immunol. 8, 856–863 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Piccand, J. et al. Rfx6 maintains the functional identity of adult pancreatic β cells. Cell. Rep. 9, 2219–2232 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Deng, Y. et al. Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function. Immunity 42, 457–470 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Wang, S. et al. FoxO1-mediated autophagy is required for NK cell development and innate immunity. Nat. Commun. 7, 11023 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Feng, X. et al. Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat. Immunol. 12, 544–550 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Narni-Mancinelli, E. et al. Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc. Natl Acad. Sci. USA 108, 18324–18329 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Bentzinger, C. F. et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell. Metab. 8, 411–424 (2008).

    CAS  PubMed  Google Scholar 

  53. Clausen, B. E. et al. Residual MHC class II expression on mature dendritic cells and activated B cells in RFX5-deficient mice. Immunity 8, 143–155 (1998).

    CAS  PubMed  Google Scholar 

  54. Ludigs, K. et al. NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. Nat. Commun. 7, 10554 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Held, W., Lowin-Kropf, B. & Raulet, D. H. Generation of short-term murine natural killer cell clones to analyze Ly49 gene expression. Methods Mol. Biol. 121, 5–12 (2000).

    CAS  PubMed  Google Scholar 

  56. Jordan, S. et al. Virus progeny of murine cytomegalovirus bacterial artificial chromosome pSM3fr show reduced growth in salivary glands due to a fixed mutation of MCK-2. J. Virol. 85, 10346–10353 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Brune, W., Hengel, H. & Koszinowski, U. H. A mouse model for cytomegalovirus infection. Curr. Protoc. Immunol. 43, 19.17 (2001).

    Google Scholar 

  58. Zurbach, K. A., Moghbeli, T. & Snyder, C. M. Resolving the titer of murine cytomegalovirus by plaque assay using the M2-10B4 cell line and a low viscosity overlay. Virol. J. 11, 71 (2014).

    PubMed  PubMed Central  Google Scholar 

  59. Masternak, K., Peyraud, N., Krawczyk, M., Barras, E. & Reith, W. Chromatin remodeling and extragenic transcription at the MHC class II locus control region. Nat. Immunol. 4, 132–137 (2003).

    CAS  PubMed  Google Scholar 

  60. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10–12 (2011).

    Google Scholar 

  61. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).

    CAS  PubMed  Google Scholar 

  62. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).

    CAS  PubMed  Google Scholar 

  63. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).

    CAS  PubMed  Google Scholar 

  64. Wasserman, W. W. & Sandelin, A. Applied bioinformatics for the identification of regulatory elements. Nat. Rev. Genet. 5, 276–287 (2004).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank M. Thome-Miazza and P. Schneider (UNIL, Lausanne); W. Reith (UNIGE Medical School, Geneva); M. Rüegg and M. Hall (Biozentrum, Basel); and M. Mazzone (VIB, Leuven) for sharing reagents important for this study. We thank N. Fonta, W. Held, R. Bedel, S. Siegert, S. Calderon, K. Harshman, and R. Hertzano for technical help. Studies in the group of G.G. were funded by the European Research Council (ERC-2012-StG310890) and the Swiss National Science Foundation (PP00P3_139094 and PP00P3_165833). S.P.M.W. is supported by the ETH post-doctoral fellowship program (FEL29 15-2) and the Horten Foundation. The laboratory of E.V. is supported by the ERC under the European Union’s Horizon 2020 research and innovation programme (grant agreement 694502), Agence Nationale de la Recherche, Innate Pharma, MSDAvenir, Ligue Nationale contre le Cancer (Equipe labelisée ‘La Ligue’) and Marseille-Immunopole. O.B. was supported by the Swiss National Science Foundation 310030-172978 and Swiss Cancer Research KFS-4136-02-2017. M.E.R. was supported by KFS-MDPhD-3557-06-2015. M.D. was supported by the Fondation Medic, Lausanne. P.-C.H. was supported by the Swiss National Science Foundation (31003A_163204), the Swiss Cancer League (KFS-3949-08-2016), and a Melanoma Research Alliance Young Investigator award.

Author information

Author notes

  1. These authors contributed equally: Wilson Castro, Sonia T. Chelbi.

Authors and Affiliations

  1. Department of Biochemistry, University of Lausanne, Epalinges, Switzerland

    Wilson Castro, Sonia T. Chelbi, Charlène Niogret, Cristina Ramon-Barros, Kevin Osterheld, Giorgia Rota, Leonor Morgado & Greta Guarda

  2. Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland

    Sonia T. Chelbi & Greta Guarda

  3. Institute of Microbiology, ETH Zürich, Zürich, Switzerland

    Suzanne P. M. Welten & Annette Oxenius

  4. Ludwig Center for Cancer Research of the University of Lausanne, Epalinges, Switzerland

    Haiping Wang, Mauro Delorenzi & Ping-Chih Ho

  5. Department of Fundamental Oncology, University of Lausanne, Epalinges, Switzerland

    Haiping Wang, Mauro Delorenzi & Ping-Chih Ho

  6. Centre d’Immunologie de Marseille-Luminy, Aix Marseille Université, Inserm, CNRS, Marseille, France

    Eric Vivier

  7. Service d’Immunologie, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, Marseille, France

    Eric Vivier

  8. Innate Pharma Research Labs., Innate Pharma, Marseille, France

    Eric Vivier

  9. Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

    Miro E. Raeber & Onur Boyman

  10. Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland

    Mauro Delorenzi & David Barras

Authors
  1. Wilson Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonia T. Chelbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charlène Niogret
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cristina Ramon-Barros
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Suzanne P. M. Welten
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kevin Osterheld
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Haiping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giorgia Rota
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Leonor Morgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Eric Vivier
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Miro E. Raeber
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Onur Boyman
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Mauro Delorenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. David Barras
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ping-Chih Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Annette Oxenius
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Greta Guarda
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

W.C., S.T.C., C.N., C.R.-B., S.P.M.W., K.O., H.W., G.R., and L.M. performed the experiments; D.B., S.T.C., and M.D. performed bioinformatics analyses; E.V., M.E.R., O.B., M.D., P.-C.H., and A.O. shared protocols, reagents, help, and advice; W.C., S.T.C., and G.G. designed the research, analyzed the data, and wrote the manuscript.

Corresponding author

Correspondence to Greta Guarda.

Ethics declarations

Competing Interests

E.V. is a cofounder, shareholder, and employee of Innate Pharma. Unrelated projects in the laboratory of G.G. are supported by OM-Pharma, Galenica, and the Novartis Foundation. Three unrelated projects in the laboratory of P.-C.H. are supported by Roche and Idorsia. O.B. is a shareholder in Anaveon AG. An unrelated project in the group of M.D. is supported by Merck KGaA, and M.D. owns stocks from the companies Novartis, Roche, and Idorsia. The other authors have no conflicting financial interest to declare.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Integrated supplementary information

Supplementary Figure 1 Rfx7 phylogeny and conditional-knockout strategy.

(a) Percent identity matrix of full RFX7 protein sequences generated with Clustal 2.1. (b) Phylogenetic tree based on full protein alignment (Neighbor-joining tree without distance corrections, Clustal 2.1); the bar line (distance scale) indicates the percentage of variation among species, i.e. 0.1 represent 10% difference between two sequences. (c) Alignment of RFX7 DNA Binding Domain for the indicated species (JalView). The compared protein sequences correspond to the following species: Human, Homo sapiens; Chimpanzee, Pan troglodytes; Gorilla, Gorilla gorilla; Macaque, Macaca mulatta; Orangutan, Pongo pygmaeus; Mouse, Mus musculus; Rat, Rattus norvegicus; Rabbit, Oryctolagus cuniculus; Guinea pig, Cavia porcellus; Pig, Sus scrofa; Cow, Bos taurus; Chicken, Gallus gallus; Xenopus, Xenopus tropicalis; Zebrafish, Danio rerio. (d) Scheme showing the targeting strategy for the conditional knockout of the murine Rfx7 gene. The vector was designed such as the 5’ loxP site is inserted upstream of exon 3 and the target region is 1.96 kb including exons 3-4. The loxP/FRT flanked Neo cassette is inserted downstream of exon 4. The selection cassette (Neo) was excised by crossing floxed mice with FLP deleter line. The two loxP sites shown allow Cre-mediated deletion of exons 3 (Ex 3) and 4 (Ex 4). PCR primers b/c discriminate wild type (wt) and floxed (fl) Rfx7 alleles and primers a/c wild type and knockout (ko) Rfx7 alleles. Arrows on diagram indicate PCR primer positions. PCR products obtained for each genotype are shown. LA: long arm, MA: middle arm, SA: short arm, FRT: flippase recognition target, Neo: neomycine cassette

Supplementary Figure 2 Rfx7 deletion is highly efficient in immune cells.

(a,b) Quantitative RT-PCR (qRT-PCR) data (relative to Polr2a) showing Rfx7 transcript abundance in MACS-sorted T and B cells (a), and in FACS-sorted NK lymphocytes (b) from Vav Rfx7fl/fl and Rfx7fl/fl mice. Results represent mean ± SD of technical replicates (n = 3) and are representative of at least two experiments (a,b)

Supplementary Figure 3 Rfx7 deficiency affects NK cells in various tissues.

(a) The abundance of Rfx7 mRNA was determined by qRT-PCR in the indicated subsets of sorted NK cells from BM or spleen (SP) of wild type mice (relative to Polr2a). (b) A representative flow cytometric plot of NK cells (gated as NK1.1+CD3–CD19–) in the blood and liver of Ncr Rfx7wt/wt, and Ncr Rfx7fl/fl mice is shown (gated on CD45+ lymphocytes). Results represent the mean ± SD of n = 3 technical replicates (a) or the mean ± SEM of n = 3 mice/group (b) and are representative of at least two independent experiments (a,b). (b) Statistical comparison between the experimental condition lacking Rfx7 and control were performed; *p ≤ 0.05; Student’s t-test

Supplementary Figure 4 Validation of genes intrinsically regulated by Rfx7.

(a) Control and Rfx7-deficient NK cells were isolated from BM (sorted as CD122+ NK1.1+) and spleen (sorted as Ncr1+ and NK1.1+) from a pool of nine Vav Rfx7 wt/wt:Vav Rfx7 fl/fl mixed BM chimeras. Transcript abundance of 12 genes, selected based on the RNA-sequencing results, was determined by qRT-PCR (relative to Polr2a). (b) MACS-sorted CD4+ and CD8+ T cells from spleens of Cd4 Rfx7wt/wt and Cd4 Rfx7fl/fl mice were tested for mRNA levels of the indicated genes by qRT-PCR (relative to Polr2a). (c) Expression of the indicated proteins in MACS-enriched T cells and T cell-depleted fractions (flow through, FT) from splenocytes of Vav Rfx7wt/wt or Vav Rfx7fl/fl mice was determined by immunoblot analysis. Actin was used as loading control. (d,e) Table illustrating the fold difference (KO:WT) detected in the RNA-sequencing for Rfx genes (d) or the indicated MHC-related genes (e) in BM or spleen NK cells. f) Graphs depict the geometric MFI of surface H2-D, H2-K, and Qa2 as detected on NK cells of the indicated genotypes and a representative histogram thereof. Results depict mean ± SD of n = 3 technical replicates per genotype/organ (a) or the mean ± SEM of n = 3 (Cd4 Rfx7wt/wt) and n = 5 (Cd4 Rfx7fl/fl) mice (b) and of n = 3 (Rfx7fl/fl), n = 3 (Vav Rfx7wt/wt) and n = 4 (Vav Rfx7fl/fl) mice (f). Results are representative of at least two independent experiments (a,b,c,f). (a,b,f) Statistical comparison between the experimental condition lacking Rfx7 and controls were performed; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001; Student’s t-test

Supplementary Figure 5 Analyses of Rfx7-target genes in silico.

(a) In Silico analysis of promoter sequences (-700; +300) of differentially expressed genes from cluster 1 (downregulated genes), cluster 2 (upregulated genes), and cluster 0 (non-modulated genes, serving as control group) was performed with JASPAR tool for the presence of putative transcription factor binding sites (TFBS) for CCAAT/enhancer binding protein beta (Cebpb) and T-box 15 (Tbx15). The box and whisker plots depict the number of putative TFBS identified with a relative profile score threshold of 0.8. Significance was determined using one-tail Mann-Whitney tests; *p ≤ 0.05

Supplementary Figure 6 Rfx7-dependent regulation of size and granularity.

(a) Quantification of forward scatter (FSC) and side scatter (SSC) for splenic NK cells (gated as NK1.1+ CD3/19-) from Ncr Rfx7wt/wt (set as 100%) and Ncr Rfx7fl/fl mice. (b) A representative ImageStream picture of NK cells (bright field or anti-NK1.1 staining) from Ncr Rfx7wt/wt and Ncr Rfx7fl/fl. Histogram illustrates the surface area based on the bright field of 30’000 to 100’000 cells per mouse and genotype and the graph a quantification thereof (each line colored in hues of red or blue represents one mouse, Ncr Rfx7wt/wt and Ncr Rfx7fl/fl, respectively). (c,d) FSC and SSC for BM NK cells (gated as CD122+ CD3/19–) are shown for Vav Rfx7wt/wt, and Vav Rfx7fl/fl mice (c) and for Ncr Rfx7wt/wt and Ncr Rfx7fl/fl mice (d). (e) Quantification of FSC and SSC for splenic CD4+ T cells (gated as CD3+CD4+), CD8+ T cells (gated as CD3+CD8+), NKT cells (gated as NK1.1+CD3+), NK cells (gated as NK1.1+CD3–), B cells (gated as CD19+), and conventional dendritic cells (DC; gated as CD11chiCD11bint–hi) from the indicated mice. (f) HEK293T cells were co-transfected with WT, NLS-mutant (m658 & 674) Rfx7, or empty (mock) and GFP-encoding vectors. After 48 hours, FSC was analyzed on the GFP+ cells, with the FSC of mock-transfected cells set at 100. (g) Quantification of FSC and SSC for splenic NK cells, CD8+ T cells, and B cells from Rfx5+/+, Rfx5+/–, and Rfx5–/– mice. (h) The graph depicts ratios of Rfx7-deficient to control living NK cells (congenically marked) co-cultured in the presence of high IL-15 and S63845 (Mcl-1 inhibitor; Cayman Chemical) for three days (normalized to initial mix). Flow cytometry plots illustrate dead cell percentage. Results represent the mean ± SEM of n = 6 (Ncr Rfx7wt/wt) and n = 7 (Ncr Rfx7fl/fl) (a,d), n = 5 (Ncr Rfx7wt/wt) and n = 8 (Ncr Rfx7fl/fl) (b), n = 5 (Vav Rfx7wt/wt) and n = 6 (Vav Rfx7fl/fl) (c), n = 8 (Rfx7fl/fl), n = 10 (Vav Rfx7wt/wt), and n = 9 (Vav Rfx7fl/fl) (e), n = 4 (Rfx5+/+), n = 7 (Rfx5+/–), and n = 6 (Rfx5–/–) mice (g) or mean ± SD of n = 4-5 technical replicates per condition (f,h) and are representative of at least two independent experiments (a-f) and a pool of two independent experiments (g,h). Statistical comparison between the experimental condition and controls were performed; ***p ≤ 0.001; Student’s t-test (a-g)

Supplementary Figure 7 Rfx7-deleted NK cells present only moderate alterations in functional features.

(a) Expression analysis of the indicated receptors on splenic NK cells (NK1.1+CD3–CD19–) from Vav Rfx7wt/wt, and Vav Rfx7fl/fl mice is depicted as percentage of positive population (for biphasic expression) or geometric MFI. (b) Percentages and numbers of NK cells (gated as NK1.1+ and CD3/19–) in the spleen of Ncr Rfx7fl/fl and Ncr Rfx7wt/wt mice treated with IL-2 complexes (cIL-2) for four days and used for B2m–/– splenocyte rejection on day 5 (presented in Fig. 8c) are depicted. (c) A representative flow cytometric plot and a quantification of IFNγ and granzyme A production by splenic NK cells of Rfx7fl/fl, Vav Rfx7wt/wt, and Vav Rfx7fl/fl mice are shown. Results represent the mean ± SEM of n = 5 (Vav Rfx7wt/wt) and n = 4 (Vav Rfx7fl/fl) (a) or n = 4 (Ncr Rfx7wt/wt) and n = 5 (Ncr Rfx7fl/fl) mice (b), or n = 4 (c) and are representative of at least two independent experiments (a-c). Statistical comparison between the experimental condition lacking Rfx7 and controls were performed; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001; Student’s t-test

Supplementary information

Supplementary Figures

Supplementary Figures 1–7 and Supplementary Tables 1 and 2

Reporting Summary

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castro, W., Chelbi, S.T., Niogret, C. et al. The transcription factor Rfx7 limits metabolism of NK cells and promotes their maintenance and immunity. Nat Immunol 19, 809–820 (2018). https://doi.org/10.1038/s41590-018-0144-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-018-0144-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing